Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

novartis europharm limited  - brolucizumab - wet macular degeneration - ophthalmologicals - beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (amd).

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

amgen europe b.v. - talimogene laherparepvec - melanoma - antineoplastic agents - imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (stage iiib, iiic and ivm1a) with no bone, brain, lung or other visceral disease.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - ophthalmologicals - eylea is indicated for adults for the treatment of:neovascular (wet) age-related macular degeneration (amd);visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo);visual impairment due to diabetic macular oedema (dme);visual impairment due to myopic choroidal neovascularisation (myopic cnv).

Uingereza - Kiingereza - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - aflibercept - solution for injection - 40mg/1ml

Israeli - Kiingereza - Ministry of Health

bayer israel ltd - aflibercept - solution for intravitreal injection - aflibercept 40 mg/ml - aflibercept - eylea is indicated for adults for the treatment of • neovascular (wet) age-related macular degeneration (amd)• visual impairment due to macular oedema secondary to retinal vein occlusion (branch crvo or central rvo)• visual impairment due to diabetic macular oedema (dme)• visual impairment due to myopic choroidal neovascularisation (myopic cnv).

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - ophthalmologicals - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5.1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5.1),visual impairment due to diabetic macular oedema (dme) (see section 5.1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.1).

Malesia - Kiingereza - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - brolucizumab -

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - cimetidine - film-coated tablet - 400 milligram(s) - h2-receptor antagonists; cimetidine

Singapoo - Kiingereza - HSA (Health Sciences Authority)

pfizer private limited - (drug product) temsirolimus - injection, solution, concentrate - 25.0mg/ml - (drug product) temsirolimus 25.0mg/ml